SCHEMBL363319

SCHEMBL363319

Clc1cc(I)cc(Cl)n1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14134960 0.85
SCHEMBL31224061 0.81
SCHEMBL8018787 0.81
SCHEMBL16603063 0.81
SCHEMBL3235903 0.77 ADORA2A (0.39)
SCHEMBL27640472 0.75 S1PR4 (0.34)
SCHEMBL18398967 0.75 SMN1; SMN2 (0.36)
SCHEMBL8344188 0.73
SCHEMBL2743753 0.72 S1PR2 (0.42)
SCHEMBL190461 0.72

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 704 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107382840-B Pyridine compound and application thereof as IDH function mutation mutant inhibitor drug 四川大学 2020-09-01 CN claimed
US-12637450-B2 Tri-substituted aryl and heteroaryl derivatives as modulators of PI3-kinase and autophagy pathways GLOBAL CANCER TECHNOLOGY INC. (US) 2026-05-26 US disclosed
US-20260138956-A1 NOVEL COMPOUNDS AND USES THEREOF RECURSION PHARMACEUTICALS INC (US) 2026-05-21 US disclosed
US-20260108482-A1 MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS ESCIENT PHARMACEUTICALS INC (US) 2026-04-23 US disclosed
EP-4727921-A1 DUAL RAF AND TUBULIN INHIBITORS AND METHODS OF USE THEREOF Deciphera Pharmaceuticals, LLC (US) 2026-04-22 EP disclosed
EP-4727920-A1 DUAL RAF AND TUBULIN INHIBITORS AND METHODS OF USE THEREOF Deciphera Pharmaceuticals, LLC (US) 2026-04-22 EP disclosed
US-12600725-B2 Selective GRP94 inhibitors and uses thereof MEMORIAL SLOAN-KETTERING CANCER CENTER (US) 2026-04-14 US disclosed
US-12570671-B2 Substituted oxoisoindoline compounds for the treatment of cancer BRISTOL-MYERS SQUIBB COMPANY (US) 2026-03-10 US disclosed
US-12565494-B2 Inhibitors of human respiratory syncytial virus and metapneumovirus MERCK SHARP & DOHME LLC 2026-03-03 US disclosed
EP-4313981-B1 3,4-DIHYDRO-2,7-NAPHTHYRIDINE-1,6(2H,7H)-DIONES AS MEK INHIBITORS PFIZER (US) 2026-02-25 EP disclosed
US-20080145699-A1 Organic Compound, Charge-Transporting Material, and Organic Electroluminescent Element PIONEER CORPORATION (JP) 2008-06-19 US disclosed
US-20080021059-A1 Antibacterial Agents PFIZER INC. (US) 2008-01-24 US disclosed
US-20080021059-A1 Antibacterial Agents PFIZER INC. (US) 2008-01-24 US disclosed
EP-1829871-A1 ORGANIC COMPOUND, CHARGE-TRANSPORTING MATERIAL, AND ORGANIC ELECTROLUMINESCENT ELEMENT Pioneer Corporation (JP) 2007-09-05 EP disclosed
EP-1820801-A1 ORGANIC COMPOUND, CHARGE-TRANSPORTING MATERIAL, AND ORGANIC ELECTROLUMINESCENT ELEMENT Pioneer Corporation (JP) 2007-08-22 EP disclosed
EP-1805142-A2 NOVEL PYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM Reddy US Therapeutics, Inc. (US) 2007-07-11 EP disclosed
US-20060186796-A1 Compound, charge transporting material and organic electroluminescent element MITSUBISHI CHEMICAL CORPORATION (JP) 2006-08-24 US disclosed
EP-1672961-A1 COMPOUND, CHARGE TRANSPORT MATERIAL AND ORGANIC ELECTROLUMINESCENT DEVICE Mitsubishi Chemical Corporation (JP) 2006-06-21 EP disclosed
US-20060084644-A1 Novel pyridine compounds, process for their preparation and compositions containing them DR. REDDY'S LABORATORIES LTD. (IN) 2006-04-20 US disclosed
WO-2006034474-A2 NOVEL PYRIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM REDDY US THERAPEUTICS, INC. (US) 2006-03-30 WO disclosed